Recent Updates — EDSA

The Board approved increases in annual base salaries for three executive officers, effective retroactively from July 1, 2026. Dr. Pardeep Nijhawan's compensation rises to $657,423, up from $357,696; Dr. Michael Brooks' salary increases to $591,681 from $335,340; and Peter Weiler's pay goes to $525,938 from $300,000. These adjustments follow the last change in 2023 and remain subject to existing employment agreements, including Dr. Nijhawan's arrangement where 90% of cash salary is issued as restricted share units. Edesa Biotech operates in the biotechnology sector, focusing on drug discovery and development.

The FDA cleared Edesa Biotech's Investigational New Drug application for its Phase 2 clinical study of EB06 in vitiligo, allowing the company to expand patient recruitment to the United States. The double-blind, placebo-controlled trial evaluates EB06, a monoclonal antibody targeting CXCL10, in up to 80 adults with moderate-to-severe nonsegmental vitiligo. Participants are randomized 1:1 to receive either EB06 or placebo every two weeks through Week 22, with the primary efficacy endpoint being the mean percent change from baseline in the Facial Vitiligo Area Scoring Index at Week 28. Topline data is anticipated by the fourth quarter of 2027. Edesa Biotech operates as a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune and inflammatory diseases.

Edesa Biotech entered into an underwriting agreement with Guggenheim Securities for a registered public offering of common shares and accompanying warrants. The company sold 3,870,500 common shares at $5.50 per share and accompanying warrants to purchase up to 3,870,500 additional shares. Additionally, the company issued pre-funded warrants to purchase up to 675,000 common shares at a combined price of $5.4999 per warrant and accompanying warrant. The underwriters received a 30-day option to purchase up to 681,825 additional shares on identical terms. Gross proceeds are expected to be approximately $25.0 million, with net proceeds estimated at $23.1 million after deducting discounts and expenses. The offering closed on or about August 21, 2026. Edesa Biotech is a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases.

Edesa Biotech reported a net loss of $5.4 million ($0.60 per share) for the third quarter ended June 30, 2026, compared to a $1.7 million loss in the prior year period. Operating expenses rose by $3.6 million to $5.5 million, driven primarily by increased R&D costs of $3.1 million to $4.0 million for preparations and manufacturing related to its Phase 2 EB06 vitiligo study. The company completed preparations for this trial and began activating investigational sites in Canada with recruitment expected soon. In its respiratory program, exploratory data showed mortality reductions for paridiprubart in ARDS patients with acute kidney injury. Cash and cash equivalents stood at $10.3 million as of June 30, 2026. Edesa Biotech is a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases.

Edesa Biotech, Inc. entered into a Securities Purchase Agreement on June 10, 2026, for a private placement of 729,241 common shares at a price of $4.69 per share for most investors and $5.21 per share for the CEO. The company expects to close the transaction, which involves an aggregate purchase price of approximately $3.5 million, by June 15, 2026, and intends to use the net proceeds to fund the advancement of its vitiligo drug candidate, paridiprubart. Edesa Biotech, Inc. is a biotechnology company focused on developing drug candidates for skin diseases.

Edesa Biotech, Inc. reported favorable exploratory data for its anti-TLR4 monoclonal antibody, paridiprubart, in patients with acute kidney injury (AKI) and respiratory distress. In a cohort of 101 patients, paridiprubart plus standard of care was associated with a 32% relative reduction in 28-day mortality (33% vs. 49% for placebo) and a 23% relative reduction in the MAKE30 composite endpoint (41% vs. 53% for placebo).